EMDAC

AcronymDefinition
EMDACEndocrinologic and Metabolic Drugs Advisory Committee (US FDA)
EMDACEMS (Emergency Medical Services) Medical Directors Association of California
EMDACEast Midlands Dog Agility Club (UK)
References in periodicals archive ?
Briefing information for the June 10, 2015, meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).
The discussion during the EMDAC meeting is "an important reminder that there is an unmet need to provide benefits beyond [hemoglobin] [A.sub.1C] control" in patients with type 2 diabetes.
(2.) "FDA Briefing Document," Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), June 2015.
The following day, the EMDAC recommended in a 12-2 vote to approve Sanofi-Aventis' new fixed-dose combination of lixisenatide and insulin glargine (Lantus), also indicated as an add-on to lifestyle management for type 2 diabetes.
Healthcare company Sanofi (NYSE:SNY) and Regeneron Pharmaceuticals reported on Tuesday the receipt of the US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommendation for the approval of the investigational therapy Praluent (alirocumab) Injection in reducing LDL-C.
M2 EQUITYBITES-June 10, 2015-Sanofi and Regeneron Pharmaceuticals wins US FDA's EMDAC recommendation for the approval of investigational therapy Praluent Injection in reducing LDL-C
According to the company, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted in favor of approval of Vimizim for use in all MPS IVA patients, voted in favor of approval for a subgroup of MPS IVA patients, while one panel member voted to not recommend approval.
FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) supports the approval of Zavesca having voted 10 to 3 in favour of it, Actelion told AWP news agency yesterday evening.
FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 12 yes, 4 no, and 1 abstention that AstraZeneca has established sufficient benefit to offset the observed risks to support the use of Crestor in men over 50 years and women over 60 years without history of cardiovascular or cerebrovascular events or coronary heart disease (CHD) risk equivalent as defined by NCEP ATP-III guidelines.